Healthcare Industry News:  Mylan Laboratories 

Biopharmaceuticals Generics FDA

 News Release - May 24, 2006

Mylan Announces Tentative Approval for Sumatriptan Succinate Tablets

PITTSBURGH, May 24 (HSMN NewsFeed) -- Mylan Laboratories Inc. (NYSE: MYL ) today announced that the U.S. Food and Drug Administration has granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Sumatriptan Succinate Tablets 25 mg (base), 50 mg (base) and 100 mg (base).



Sumatriptan Succinate Tablets are indicated for the acute treatment of migraine headaches. They are the generic version of GlaxoSmithKline's Imitrex® Tablets, which had annual U.S. sales of approximately $878 million as of March 31, 2006.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries: Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.

For more information about Mylan, please visit www.mylan.com.



Source: Mylan Laboratories

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.